New guest article: Top 100 therapeutic trials in PAIS. Dr Fred Dejonckheere analyses the global pipeline for #MECFS, #LongCovid, POTS and fibromyalgia. Is a new pharmaceutical market segment emerging here? https://t.co/O9ZVh1B7Ej
1/3 Severely ill ME/CFS patients are the focus of Wirth & Steinacker’s new preprint. Strong loss of force, major cause of bedriddenness, is only partially explained by mitochondrial dysfunction. Evidence is provided for muscle depolarization as an additional aggravating mechanism
2/3Depolarization of skeletal muscle membrane by insufficient Na+/K+-ATPase activity, same cause as for mitochondrial dysfunction, leads to loss of force and worsens mitochondrial dysfunction even further.
Die Arbeit im @BMG_Bund geht weiter, Wahlkampf ist nicht alles. Heute Gespräch mit Prof. Wirth von Mitodicure zu MDC002. Der Wirkstoff ist einer der wichtigen Hoffnungsträger für die Behandlung von #LongCovid. Ich unterstütze bei der Beschaffung von Risikokapital.
Review article by Carmen Scheibenbogen and Klaus Wirth, #mitodicure, shows that #MECFS is an Acquired Mitochondrial Myopathy. Mitodicure is a startup which develops a breakthrough drug to correct the key pathomechanisms maintaining ME/CFS.
#LongCovid#BMBF
https://t.co/Aef9kWkFqe
#mitodicure launched its website: https://t.co/tuoSweU0pK
We are the only #MECFS start-up company worldwide developing a novel targeted drug. Support innovative drug development aimed at healing ME/CFS, which is also the most severe form of #LongCovid.
#BMBF#MECFSAwarenessDay